CVS Health Stock Trades Near $94 Despite Operating Efficiency Gains

CVS Health's management recently made an unusual comment at the Wells Fargo 21st Annual Healthcare Conference. They stated that medical costs are still in a 'high trend' environment, which dragged down managed care peers like UnitedHealth and Humana.

However, despite this cautious tone, the company detailed how it has pushed operating efficiency to new levels. Provider credentialing now takes just one day, compared to 30-120 days previously, and pre-authorizations are approved within 24 hours over 90% of the time.

This is thanks in part to AI deployments, which have allowed CVS to reinvest $1 billion in annual productivity. The company's Q2 2026 revenue rose 7.3% year-over-year, with adjusted EPS increasing by more than 40%. Management raised full-year adjusted EPS guidance to between $7.90 and $8.10.

The stock currently trades at around $94.66, which is a discount to insurer peers. CVS carries more debt and has a messier segment mix, but it still grows adjusted EPS by 40% and guides towards mid-teens growth through 2028.